Etid klinik pou Atak kè nan Kalifòni
5 etid pou Atak kè ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
Tèks ofisyèl etid la (Anglè)
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- National Institute of Clinical Research, Bakersfield
- California Institute of Renal Research, Chula Vista
- The Medical Research Group, Inc., Fresno
- ak 27 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05485961An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Cardiovascular Res Found, Beverly Hills
- National Heart Institute, Beverly Hills
- Diabetes Lipid Management Center, Huntington Beach
- ak 7 plis
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 4, 2026 · NCT07517263OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- National Heart Institute, Beverly Hills
- 310 Clinical Research, Inglewood
- University of California San Diego, La Jolla
- ak 11 plis
Ap rekriteFaz 3
Laj 50 a 105 · Tout sèks · Mizajou Aug 21, 2026 · NCT07136012AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
- Orange County Heart Institute, Orange
- Peerbridge Health, Pasadena
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jun 1, 2026 · NCT06699056Focused Orticumab Research for Treating Inflammation in Coronary Arteries
- Abcentra Investigational Site, Los Angeles
- Abcentra Investigational Site, Torrance
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 27, 2026 · NCT06927739Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.